⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7339900 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL1936777 | 0.91 | — | — | |
| SCHEMBL275276 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL5860637 | 0.78 | — | — | |
| SCHEMBL382097 | 0.77 | — | — | |
| SCHEMBL525878 | 0.77 | — | — | |
| SCHEMBL458244 | 0.63 | — | — | |
| Fluoride Ion SCHEMBL4426055 | 0.59 | SLC34A1 (0.36) | — | |
| SCHEMBL28317135 | 0.59 | — | — | |
| Fluoride Ion SCHEMBL20723412 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752496-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161280-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | claimed |
| EP-4208465-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Orexia Therapeutics Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| EP-3502111-B1 | PDE4 INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-07-27 | — | — | EP | disclosed |
| EP-3353176-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-01-19 | — | — | EP | disclosed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3353178-B1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| WO-2020168017-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-3661923-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-RE47636-E1 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-3502111-A1 | PDE4 INHIBITOR | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-26 | — | — | EP | disclosed |
| EP-1196440-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA Technology Ltd. (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1187825-A1 | THIOPHENE INTEGRIN INHIBITORS | Shire Biochem Inc. (CA) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001000671-A1 | DERIVATIVE COMPOUNDS | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000655-A2 | THERAPEUTIC PEPTIDES DERIVED FROM SUBSEQUENCES OF BPI | XOMA TECHNOLOGY LTD. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1061904-A1 | NANOPARTICLES, METHOD FOR PRODUCING NANOPARTICLES AND USE OF THE SAME | Aventis Research & Technologies GmbH & Co KG (DE) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000075129-A1 | THIOPHENE INTEGRIN INHIBITORS | SHIRE BIOCHEM INC. (CA) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999013898-A9 | EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS | NIEWIAROWSKI STEFAN (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999047130-A1 | NANOPARTICLES, METHOD FOR PRODUCING NANOPARTICLES AND USE OF THE SAME | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO. KG (DE) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999013898-A1 | EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS | NIEWIAROWSKI STEFAN (US) | 1999-03-25 | — | — | WO | disclosed |